ENJAYMO FDA approval date

The FDA approved ENJAYMO on 4 Feb 2022.

FDA approval date
4 Feb 2022

Drug identity has not yet been verified against registry records

Also recorded as SUTIMLIMAB-JOME

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-02-04DayENJAYMOFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761164", "applicant_as_listed_by_fda": "RECORDATI RARE DISEASES, INC.", "brand_names": ["ENJAYMO"], "active_ingredients": ["SUTIMLIMAB-JOME"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220204", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026